|
TABATA Tsutomu
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor and Division head |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Presence of invitation | Invited paper |
| Title | Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer. |
| Journal | Formal name：The journal of obstetrics and gynaecology research Abbreviation：J Obstet Gynaecol Res ISSN code：14470756/13418076 |
| Domestic / Foregin | Domestic |
| Volume, Issue, Page | pp.1-7 |
| Author and coauthor | Hirata Toru, Kondo Eiji, Magawa Shoichi, Kubo-Kaneda Michiko, Nii Masafumi, Yoshida Kenta, Maezawa Tadashi, Tabata Tsutomu, Ikeda Tomoaki |
| Authorship | Corresponding author |
| Publication date | 2022/08 |
| Summary | AIM:To investigate the recurrence rate, live-birth rate, and treatment outcomes of levonorgestrel-releasing intrauterine device (LNG-IUD) for the management of atypical endometrial hyperplasia (AEH) or Grade-1 endometrial cancer (EC) in patients who desire fertility-sparing treatment and those seeking conservative treatment without fertility preservation.METHODS:We prospectively enrolled nine patients from a single institution between April 2009 and September 2013 who were followed up for 60 months after LNG-IUD insertion.RESULTS:The median patient age was 35 (range: 29-39) years. The overall recurrence rate was 56% (5/9). The median interval between removal of the LNG-IUD and recurrence was 20.5 (range: 2-30) months. Three of the nine patients had Grade-1 EC, and six had AEH. The response rates to the LNG-IUD in patients with Grade-1 EC and AEH were 66% and 100%, respectively. Four patients (three with AEH, one with Grade-1 EC) experienced recurrence 6 months after MPA treatment and all 4 (100%) had complete response. Eight patients desired fertility preservation, of which 37% (3/8) conceived after receiving fertility treatment and 25% (2/8) had a live birth; the remaining three had previously received MPA for 6 months and had a recurrence; of these, 1 had a live birth.CONCLUSION:LNG-IUD is effective for the management of AEH and EC in young patients who desire fertility-sparing treatment, including those ineligible for MPA owing to the presence of comorbidities and those with recurrence after MPA treatment (6-month treatment), and patients seeking conservative treatment without fertility preservation. |
| DOI | 10.1111/jog.15408 |
| PMID | 36054237 |